Method for treatment of tumor by using recombinant oncolytic virus in combination with small-molecule anticancer drug

A method for treatment of a tumor by using a recombinant oncolytic virus in combination with a small-molecule anticancer drug, wherein the small-molecule anticancer drug and the recombinant oncolytic virus are used in combination to treat the tumor;

• the small-molecule anticancer drug comprises a small-molecule anticancer drug targeting ALK, a small-molecule anticancer drug targeting BTK, a small-molecule anticancer drug targeting EGFR, a small-molecule anticancer drug targeting FGFR, a small-molecule anticancer drug targeting HER2, a small-molecule anticancer drug targeting Parp, a small-molecule anticancer drug targeting PI3K, a small-molecule anticancer drug targeting VEGFR, a small-molecule anticancer drug targeting CDK4/6, and a small-molecule anticancer drug targeting KRAS;
• the recombinant oncolytic virus comprises an M protein, a G protein, an N protein, a P protein, and an L protein;
• compared to an amino acid sequence shown in SEQ ID NO 1,
• the M protein comprises any one or more site mutations of M51R, V221F and S226R;
• or
• the M protein comprises any one or more site mutations of N32S, N49D, M51R, H54Y, V221F, V225I and S226R;
• or
• the M protein comprises any one or more site mutations of N32S, N49D, M51R, H54Y, knockouting of bases encoding leucine at position 111, V221F, V225I and S226R;
• or
• the M protein comprises any one or more site mutations of N32S, N49D, M51R, H54Y, L111A, V221F, V225I and S226R;
• or
• the M protein comprises any one or more site mutations of G21E, N32S, N49D, M51R, H54Y, V221F, V225I and S226R;
• or
• the M protein comprises any one or more site mutations of G21E, N32S, M33A, N49D, M51R, H54Y, V221F, V225I and S226R;
• or
• the M protein comprises any one or more site mutations of G21E, N32S, M33A, N49D, M51R, H54Y, A133T, V221F, V225I and S226R;
• or
• the M protein comprises any one or more site mutations of N32S, M33A, N49D, M51R, H54Y, V221F, V225I and S226R;
• or
• the M protein comprises any one or more site mutations of N32S, M33A, N49D, M51R, H54Y, A133T, V221F, V225I and S226R;
• or
• the M protein comprises any one or more site mutations of N32S, N49D, M51R, H54Y, A133T, V221F, V225I and S226R;
• compared to an amino acid sequence shown in SEQ ID NO 12, the G protein comprises any one or more site mutations of V53I, A141V, D172Y, K217E, D232G, V331A, V371E, G436D, T438S, F453L, T471I, and Y487H;
• compared to an amino acid sequence shown in SEQ ID NO 14, the N protein comprises any one or more site mutations of 114V, R155K and S353N;
• compared to an amino acid sequence shown in SEQ ID NO 16, the P protein comprises any one or more site mutations of R50K, V76A, D99E, L126S, L140S, H151Y, 1168M, K170E, Y189S, and N237D;
• and
• compared to an amino acid sequence shown in SEQ ID NO 18, the L protein comprises any one or more site mutations of S87P and I487T.